At only 450mcap is Corbus Pharmaceuticals undervalued?
1) Corbus is different from other cannabis stocks as they are designing therapies around marijuana to treat fibrotic diseases. If these therapies work, some analysts put the value of their potential sales at 2BN a year.
2) At a small marketcap of 450m, Corbus could be a real untouched gem in the cannabis industry, compared to its competitors with 4BN+ marketcap.
3) After an agreement with Japananese Kaken Pharmaceutical, Corbus is on the way to receive an additional 173m upon achievement of various milestones
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.